Vascularization Inhibitors

• US 20130236889A1
• Filed: 08/08/2011
• Published: 09/12/2013
• Est. Priority Date: 03/24/1998
• Status: Abandoned Application

• Current Assignee: Kazunobu Tachibana, Tadamitsu Kishimoto, Takashi Nagasawa
• Original Assignee: Kazunobu Tachibana, Tadamitsu Kishimoto, Takashi Nagasawa
• Inventors: Kishimoto, Tadamitsu, Nagasawa, Takashi, Tachibana, Kazunobu
• Application Number:
  US13/205,144
• Publication Number:
  US 20130236889A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity

Abstract

This invention provides a therapeutic agent for inhibiting neovascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, and a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4.

Based on the finding that vascularization is suppressed in CXCR4 knockout mice, it becomes possible to prepare a therapeutic agent for suppressing vascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, each of which comprises as the effective ingredient, a substance that inhibits the action of CXCR4, as well as to prepare a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Methods for treatment are made possible that use these therapeutic agents.

Claims

1-27. -27. (canceled)

28. A method for screening a substance that inhibits vascularization, treats a solid cancer or treats a disease pathologically caused by neovascularization, based on the inhibition of the action due to CXCR4, which comprises a step of identifying a substance that inhibits the action due to CXCR4 as a substance that inhibits vascularization, treats a solid cancer or treats a disease pathologically caused by neovascularization.

29. The method according to claim 28, which comprises a step of identifying a substance that inhibits (1) the binding between SDF-1 and CXCR4, (2) the signaling from CXCR4 to nuclei, (3) the expression of CXCR4, or (4) the expression of SDF-1 as a substance that inhibits vascularization, treats a solid cancer or treats a disease pathologically caused by neovascularization.

30. A method for evaluating vascularization inhibitory activity, anti-solid tumor activity or anti-disease pathologically caused by neovascularization activity of a substance, based on the inhibition of the action due to CXCR4, which comprises a step of measuring the inhibitory activity of the action due to CXCR4.

31. The method according to claim 30, which comprises a step of measuring the inhibitory activity of (1) the binding between SDF-1 and CXCR4, (2) the signaling from CXCR4 to nuclei, (3) the expression of CXCR4, or (4) the expression of SDF-1.